>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: EOPN -41%, FIVE -15.2%, (reports Holiday sales increased 24.5% y/y to $230.7 mln; Comp store sales over same period grows 3.2%; Guides Q4 slightly below consensus), TCS -10.4%, RT -8.5%, VOXX -5.9%, BBBY -4.3%, M -3%, (reaffirms FY15 EPS guidance; Nov/Dec comps +2.1%, in-line with Q4 comps guidance), SYRG -1.9%,ABBV -0.6%, IMOS -0.6%,

M&A news: XL -2.6% (acquires Catlin Group; transaction equity value of ~$4.1 bln)

Select metals/mining stocks trading lower: CLF -2%, MT -1.6% VALE -1.6%, RIO -1%, BHP -0.9%.

Select oil/gas related names showing early weakness: SDRL -1.4%, STO -1.0%, TOT -0.9%, RDS.A -0.9%, BP -0.8%.

Other news: CNAT -42.3% (announces top-line results from ACLF and organ impairment clinical trials of emricasan), WTSL -32.1% (WSJ details news that WetSeal (WTSL) may soon file for bankruptcy), ARGS -27.2% (provides an update on its clinical research program for AGS-004; primary endpoint of the trial was not achieved), IDN -27.1% (files amended S-1), ADMP -22% (to offer shares of its common stock in an underwritten public offering; size not disclosed), SBLK -18.1% (plans to make an underwritten public offering of its common stock; size not disclosed ), CTSO -8.8% (attributed to pricing of seconday), GMLP -7.4% (Golar LNG Partners announces secondary offering of 7,170,000 common units by Golar LNG Limited), CCU -5.3% (reports that preliminary fourth quarter volume variations were up 1.6% and the twelve month period ended December 31st, 2014 were up 4.5%), SAN -5% (trading lower in Europe following yday's news of capital raise), EFC -3% (reports estimated book value per common share as of Dec 31 was $23.42, or $23.13 on a diluted basis), ADHD -2.8% (announced it intends to offer its ordinary shares in a public offering; terms not disclosed), GWPH -2% (cont weakness), SBUX -1.6% (announced COO Troy Alstead is taking an extended unpaid leave from the co, effective March 1, 2015), TSLA -1.2% (Germany registrations have been disappointing, according to reports), OC -1.1% (small pull back following recent run up), SAVE -1% (reported preliminary traffic results for December 2014; Traffic in December 2014 increased 17.7% versus December 2013 on a capacity increase of 20.1%), APOL -0.7% (President Obama has proposed to make community college free for responsible students for 2 years)

Analyst comments: NUAN -3.1% (downgraded to Sell from Neutral at Goldman), CROX -2.7% (downgraded to Neutral from Overweight at Piper Jaffray), HOT -1.7% (ddowngraded to Neutral from Overweight at JP Morgan), LVS -1.7% (downgraded to Equal-Weight from Overweight at Morgan Stanley), FGEN -1.3% (downgraded to Neutral from Buy at Goldman), SPLS -0.9% (downgraded to Neutral from Outperform at Credit Suisse)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: SD +10%, (SandRidge Energy, Inc. Updates Shareholders on Financial Results for Q3), HELE +5.6%, INFY +5.3%, HURC +5%, UMC +3.8%, BOOT +3.6%, BAMM +1.8%, (reports holiday comps for 9 wk period ending 1/3 were +1.2% Y/Y and +1.7% excluding e-Reader devices), AZZ +1.3%

M&A news: RRTS +5.1% hearing M&A speculation as catalyst)

Other news: CERE +37.5% (favorable results from its biotech corn evaluations in China ), AGEN +33.6% (Agenus and and Incyte (INCY) announce a global license, development and commercialization agreement), PTLA +13% (announces Phase 3 ANNEXA-R study of andexanet alfa and factor Xa inhibitor XARELTO met primary endpoint with high statistical significance), RVNC +9.5% (announces publication of positive results from RT002 Phase 1/2 study in which RT002 achieved median duration of 7 mos, met its efficacy and safety endpoints), ARNA +4.2% (confirms in filing that following its data release on the 7th from its Phase 1b trial for APD334), PRTO +3.9% (announced publication of nonclinical data on PRT-201 in peripheral artery disease), BIND +3.5% (cont volatility following yday's move), KBIO +3.1% (CEO David W. Pritchard announced retirement), CY +1.7% (favorable commentary on Thursday's Mad Money), TNXP +1.6% (completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201), GILD +1.4% (seeing reports that health insurer Anthem has selected Harvoni as hepatitis C drug of choice)

Analyst comments: YELP +3.1% (upgraded to Buy from Neutral at BofA/Merrill), CARA +2.7% (initiated with a Buy at Canaccord Genuity), WYNN +2.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley), PGH +2.1% (upgraded to Overweight from Equal Weight at Barclays), KITE +1.7% (initiated with a Buy at Mizuho), FCAU +1.5% (upgraded to Neutral from Underperform at Credit Suisse), GMCR +0.9% (initiated with a Buy at UBS)